Mayer Brown has advised new client Oxford BioDynamics Plc (“OBD”), an Oxford University spin-out, on its admission to AIM with an expected market capitalization of £136 million.

OBD is a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. OBD’s proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

OBD will use the proceeds raised from listing on AIM to accelerate its growth strategy for its EpiSwitch™ technology. Admission to trading on AIM is expected to take place on 6 December 2016.

The Mayer Brown team was led by Corporate & Securities partner Robert Hamill and included Corporate & Securities senior associate Rebecca Bothamley and associate Harriet Hainsworth; IP partner Mark Prinsley and associate Daniel Gallagher; and Employment & Benefits consultant Andrew Stanger, and senior associates Elizabeth Hodgkinson and Nicola Thomson.